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ABSTRACT  
The derivative spectrophotometric method was developed and applied for the simultaneous determination of 
Atenolol (ATE) and Hydrochlorothiazide (HCT) in Tablets formulations. The first derivative spectrophotometric 
(1DS) method was applied for the determination of (ATE) and (HCT), respectively. (ATE) was determined at 
271.9 nm (1D 271.9) and (HCT) was determined at 279.3 nm (1D 279.3). Linearity showed a good correlation 
coefficients R2 = 0.9994 and R2 = 0.9989 for (ATE) and (HCT), respectively. Linearity ranges were (10 – 280) 
𝜇g/mL for (ATE) and (2 – 20) 𝜇g/mL for (HCT). The limit of detection (LOD) and limit of quantification (LOQ) 
were to be 2.77 𝜇g/mL and 8.38 𝜇g/mL for (ATE), 0.52 𝜇g/mL and 1.59 𝜇g/mL for (HCT), respectively. The 
proposed first derivative method was successfully applied to determine (ATE) and (HCT) in one Syrian 
trademark drug such as: (NORMOTIC 100 mg (ATE) and 25 mg (HCT)/tab.). All studied samples showed that 
the drug level was conformed to British Pharmacopeia. 
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INTRODUCTION 
Atenolol (ATE) chemically, 4-(2-hydroxy-3-isopropyl aminopropoxy)-phenyl acetamide is a  β-adrenoreceptor 
blocking agent, primarily used in hypertension, angina pectoris and myocardial infraction. It mainly acts by 
inhibition of rennin release and angiotensin-2 & aldosterone production. It is reported to lack intrinsic 
sympathomimetic activity and membrane-stabilizing properties.  
Hydrochlorothiazide (HCT), 6-chloro-3, 4-dihydro-2H-1, 2, 4-benzothiadiazine-7-sulfonamide  1, 1-dioxide, 
which is widely used in antihypertensive pharmaceutical preparations, reduces active sodium reabsorption and 
peripheral vascular resistance.  
The review of the literature revealed that no method is yet reported for the simultaneous estimation of both 
drugs in combined dosage forms. Present work describes two simple, accurate, reproducible, rapid and 
economical methods for simultaneous estimation of (ATE) and (HCT) in tablets formulation1. 
Thus, various methods have been proposed to determine the amount of (ATE) and (HCT) in some 
pharmaceutical formulations, such as reverse phase high performance liquid chromatographic method (RP-
HPLC)2-3-4, high performance liquid chromatographic method (HPLC)5, spectrophotometric method (UV)1-6-7, 
Liquid chromatographic method (LC)8, Ultra performance liquid chromatographic method (ULPC)9 are 
successfully applied to determine the two compounds. 
The aim of this work is to develop a simple and accurate spectrophotometric method for simultaneous 
determination of (ATE) and (HCT) in one pharmaceutical formulations without prior treatment by derivative 
spectrophotometry (1DS). 
MATERIALS AND METHODS 
Apparatus 
All spectral measurements were carried out using a T80+, UV/Vis spectrophotometer PG instrument Ltd (UK), 
connected to computer, quartz cells 1 cm. Ultrasonic bath Daihan (China), and stirrer Velp Scientifica (Europe). 
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Chemical regents: 
Methanol from LOBAL Chemie (INDIA), Hydrochloric acid from SURCHEM PRODUCTS LTD (ENGLAND), 
Hydrochlorothiazide purity 99.38 % was obtained from China and Atenolol purity 100.42 % was obtained from 
India, Double distilled water.   
Stock standard preparation 
Stock solution 1.5 × 10-2 M of Atenolol (MW = 266.341 g/mol) was prepared by dissolving  400 mg of Atenolol 
standard material in volumetric flask 100 mL of Methanol. The working standard solutions were prepared by 
appropriate dilutions of stock solution 1.5 × 10-2 M with   (0.1 N) HCl  to give concentrations between (10 - 
280) 𝜇g/mL of (ATE). 
Stock solution 6.76 × 10-4 M of Hydrochlorothiazide (MW = 297.73 g/mol) was prepared by dissolving 20 mg of 
Hydrochlorothiazide equivalent to 20.125 mg (after taking the purity in consideration) in volumetric flask 100 
mL of Methanol. The working standard solutions were prepared by appropriate dilutions of stock solution 6.7 
× 10-4 M with (0.1 N) HCl to give concentrations between (2 - 20) 𝜇g/mL of (HCT). 
Calibration Curve 
To construct the calibration curve, ten standard solutions for each concentration were prepared and the 
absorbance was measured of each solution five times. 
Sample preparation 
One Syrian product was studied: 
Ten NORMOTIC tablets were weighed and finely powdered and an accurate weight equivalent to one tablet 
100 mg (ATE) and 25 mg (HCT) was accurately weighed and dissolved in 25 mL Methanol. The sample solution 
was filtered through a filter papers (Whatman 3, England). Then 0.1 mL was taken to 10 mL volumetric flask 
and adjusted to volume with (0.1 N) HCl. It was theoretically equivalent to 40 𝜇g/mL of (ATE) and 10 𝜇g/mL of 
(HCT). 
RESULTS AND DISCUSSION 
Absorption spectra of the standard raw material 120 𝜇g/mL (ATE) and 10 𝜇g/mL (HCT) solutions were 
recorded within a wavelength range of (265 - 300) nm against the blank: (Methanol + (0.1N) HCl). It was 
noticed that (ATE) and (HCT) cannot be determined by direct measurement, because of the overlapped 
spectra.  
On the other hand, derivative spectrophotometry showed more resolution, where the determination of (ATE) 
and (HCT) mixture was possible without pretreatment. 
The first derivative spectrum at zero-crossing point was used to determine (ATE) in the presence of  (HCT) at 
271.9 nm 
 “Fig. 1, a”, and determine (HCT) in the presence  of (ATE) at 279.3 nm “Fig. 1, b”. 
 
Fig. 1: First derivative spectra of: a- (ATE), b- (HCT). 
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METHOD VALIDATION 
The validity of the proposed method was assessed by accuracy (reported as recovery percentage), precision                
(reported as RSD %), linearity (evaluated by regression equation), limit of detection (LOD) and limit of 
quantification (LOQ). 
Linearity 
The concentration linearity of (ATE) was in the range (10 - 280) 𝜇g/mL at 271.9 nm by 1D271.9,” Figs. 2,3” and 
the concentration linearity of (HCT) was in the range (2 - 20) µg/mL at 279.3 nm by 1D279.3, “Figs. 4, 5”.  
  
         Fig. 2: First derivative spectra of (ATE): 
                    C1: 10 𝜇g/mL, C2: 40 𝜇g/mL,  
                    C3: 120 𝜇g/mL, C4: 200 𝜇g/mL, 
                    C5: 280 𝜇g/mL. 
   Fig. 3: Calibration curve for (ATE): 
               C1: 10 𝜇g/mL, C2: 20 𝜇g/mL,  
               C3: 30 𝜇g/mL, C4: 40 𝜇g/mL,  
               C5: 80 𝜇g/mL, C6: 120 𝜇g/mL,  
               C7: 160 𝜇g/mL, C8: 200 𝜇g/mL,     
               C9: 240 𝜇g/mL, C10: 280 𝜇g/mL.          
               n = 5  for each concentration.       
 
  
Fig. 4: First derivative spectra of (HCT): 
           C1: 2 𝜇g/mL,   C2: 6 𝜇g/mL,  
           C3: 10 𝜇g/mL, C4: 14 𝜇g/mL, 
Fig. 5: Calibration curve for (HCT). 
C1: 2 𝜇g/mL,  C2: 4 𝜇g/mL, 
C3: 6 𝜇g/mL,  C4: 8 𝜇g/mL, 
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           C5: 18 𝜇g/mL.  
 
C5: 10 𝜇g/mL, C6: 12 𝜇g/mL, 
C7: 14 𝜇g/mL, C8: 16 𝜇g/mL, 
C9: 18 𝜇g/mL, C10: 20 𝜇g/mL.                                                                                         
            n = 5 for each concentration. 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
LOD and LOQ were calculated in “table 1” using the following equations:        
LOQ = 10 × SD    
                         m 
LOD = 3.3 × SD 
                         m 
Where SD is the standard deviation of y-intercepts (a) of regression lines and (b) is the slope of the equitation 
of calibration curve, y = a + b x.  
Table 1: Statistical data for calibration graphs 
Method Analyte 
Selected 
wavelength 
(nm) 
Linearity rang 
𝜇g/mL 
Correlation coef. (R2) LOD 𝜇g/mL LOQ 𝜇g/mL 
DS ATE 1D 271.9 10 – 280 0.9994 2.77 8.38 
DS HCT 1D 279.3 2 – 20 0.9989 0.52 1.59 
Accuracy 
To determine the precision and accuracy of the proposed method, five replicate determinations were carried 
out on three different concentrations of standards (ATE) and (HCT). The validation results are shown in “table 
2”. 
Table 2: Method validation for the simultaneous determination of Atenolol and Hydrochlorothiazide by 
the 1DS 
DS 
Pharmaceutically 
Raw material 
Theoretical 
concentration 
(μg/mL) 
observed concentration 
 (μg/mL) 
SD 
µg/mL 
Precision 
RSD  
(%) 
Accuracy 
(%) 
 
1D271.9 
 
Atenolol 
80 82.28 2.06 2.50 102.85 
160 165.17 2.00 1.21 103.23 
240 244.35 1.52 0.62 101.81 
 
1D279.3 
 
Hydrochlorothiazide 
4 3.99 0.03 0.75 99.75 
8 8.33 0.10 1.20 104.12 
12 12.27 0.15 1.22 102.25 
Accuracy (%) = (observed concentration/theoretical concentration) ×100.  
 Five separate determinations were performed and calculated the mean.  
Precision 
In order to demonstrate the precision of the proposed method, intra-day and inter-day variability were 
performed at three different concentrations (40, 120, and 200 𝜇g/mL) for Atenolol and (6, 10, and 14 𝜇g/mL) 
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for Hydrochlorothiazide at the same day and at three different days. Method precision was tested in terms of  
RSD % for both intra-day and inter-day precisions. 
The precision was ascertained by carrying out five replicates of standard Atenolol and Hydrochlorothiazide 
under study and the mean was calculated. The RSD % results were not more than 4.51 %, 3.58 % for (ATE) and 
(HCT) respectively during the determination in one day and the RSD % results were not more than 4.54 %, 3.45 
% for (ATE) and (HCT) respectively during the determination in three days, where the method is considered 
very precise. 
Recovery 
The recovery was studied by three addition standards of each (ATE) and (HCT) in the NORMOTIC product. 
“Table 3” presents the recovery result for the NORMOTIC Syrian trademark drug. 
Table 3: Recovery for NORMOTIC Syrian trademark drug. 
Recovery 
Average 
% 
RSD 
% 
SD 
µg/mL 
Recovery  
% 
Total 
Found 
  
µg/mL 
Added 
µg/mL 
Sample 
µg/mL 
pharmaceutical 
compounds 
Product 
98.94 
3.65 3.59 98.46 53.63 24 
30 ATE 
NORMOTIC 100 mg 
(ATE) and 25 mg 
(HCT)/tab. 
3.53 3.49 98.93 59.68 30 
3.52 3.50 99.42 65.79 36 
100.42 
0.78 0.79 101.5 13.59 6 
7.5 HCT 0.53 0.53 99.87 14.99 7.5 
1.12 1.12 99.89 16.49 9 
 Five separate determinations were performed and calculated the mean.  
Application 
The developed method was applied for quantitative determination for (ATE) and (HCT) in NORMOTIC Syrian 
trademark as tablets formulation. The sample was prepared as described in the section of sample preparation. 
Quantitative analysis was done by using calibration curves.  
The obtained results are summarized in “table 4” for five different NORMOTIC batches. The concentrations of 
detected (ATE) and (HCT) in the NORMOTIC product was within the allowed limits under the British 
Pharmacopeia10. The relative standard deviations RSD % (n = 5) of the quantitative results were in the range of  
2.50 – 4.74 % and 0.95 – 2.18 % for (ATE) and (HCT), respectively.  
Table 4: Results of (ATE) and (HCT) in (NORMOTIC 100 mg (ATE) and 25 mg (HCT)/tab), for five different 
batches. 
No. of batches ATE 100 mg/tab. HCT 25 mg/tab. 
Result dose 
  mg/tab. 
SD 
mg/tab. 
RSD % Per % 
Result dose 
 mg/tab. 
SD 
mg/tab. 
RSD % Per % 
1 102.62 2.57 2.50 102.62 25.12 0.39 1.55 100.48 
2 103.14 3.82 3.70 103.14 25.25 0.38 1.50 101.00 
3 98.33 3.77 3.83 98.33 25.12 0.24 0.96 100.48 
4 101.46 3.46 3.41 101.46 25.22 0.55 2.18 100.88 
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5 99.01 4.69 4.74 99.01 25.42 0.36 1.42 101.68 
Range mg/tab 98.33 – 103.14 25.12 – 25.42 
Range Per % 98.33 – 103.14 100.48 – 101.68 
Range RSD % 2.50 – 4.74 0.96 – 2.18 
 Five separate determinations were performed and calculated the mean.  
According to British Pharmacopeia, the tablets must contain not less than 92.5 percent and not more than 
107.5 percent of labeled amount for (ATE) and the tablets must contain not less than 92 percent and not more 
than 107 percent of labeled amount for (HCT). So the obtained results are conformed to British Pharmacopeia 
10. 
CONCLUSION 
Atenolol (ATE) and Hydrochlorothiazide (HCT) combination were estimated in one local pharmaceutical 
product by the first derivative spectrum method, using the zero-crossing point. 
The active substances (ATE) and (HCT) in NORMOTIC pharmaceutical product were within the permissible 
limits set by the British Pharmacopeia legislation. The proposed method for estimating the binary mixture 
(ATE) and (HCT) is accurate, sensitive, simple, straight forward in quantitative analysis without prior chemical 
treatment. In general the dosage ratio of (ATE) to (HCT) is bigger in all pharmaceutical tablets formulations.  
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